News|Videos|March 26, 2024

Keytruda Combo Beneficial ‘Irrespective of PD-L1’ in Endometrial Cancer

Adding Keytruda to chemotherapy improved survival outcomes in patients with endometrial cancer, regardless of their mismatch repair or PD-L1 status.

Keytruda (pembrolizumab) plus chemotherapy improved survival in patients with endometrial cancer, according to findings from the phase 3 NRG-GY018/KEYNOTE-868 trial presented at the 2024 SGO Annual Meeting on Women's Cancer.

The drug combination tended to improve overall survival (time from treatment until death of any cause) and progression-free survival (time from treatment until death or disease worsening). Researchers observed these findings were seen across disease subtypes, including patients with DNA mismatch repair-proficient and -deficient disease, as well as those with or without PD-L1 positivity.

Keytruda is an immunotherapy drug that works by blocking the interaction between the PD-1 and PD-L1 proteins. In doing so, the drug eliminates the cancer cells’ ability to hide from the immune system. Interestingly, the NRG-GY018 trial demonstrated benefits from Keytruda regardless of their cancer’s PD-L1 expression, explained study author, Dr. Ramez N. Eskander, assistant professor of obstetrics, gynecology and reproductive sciences at the University of California San Diego Health.

“The relevance of PD-L1 molecular testing in endometrial cancer really has not been established, meaning the therapeutic information it may provide us to make a therapeutic decision has not been adjudicated or determined,” Eskander explained in an interview.

Transcript:

The relevance of PD-L1 molecular testing in endometrial cancer really has not been established, meaning the therapeutic information it may provide us to make a therapeutic decision has not been adjudicated or determined. There are some clinical trials, I will say the DUO-E trial, which suggested that utilizing their assay, which was a TAP score, may inform benefit, although when we looked at this and NRG-GY018, and [also] in prior endometrial cancer trials looking at immunotherapy, we didn't see that PD-L1 expression status informed efficacy. In the RUBY trial, when they presented data at this annual meeting, SGO 2024, similarly, they did not see that PD-L1 expression by a [combined positive score] informed the therapeutic benefit of immunotherapy.

So, at this time, there is no strong evidence that suggests that we should be using PD-L1 status to inform utilizing this combinatorial approach. In fact, I would argue that the strongest evidence we have from these trials suggests that the combination would be appropriate irrespective of PD-L1 expression.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.


Related to this article

Image of of hot flashes
Hot flashes are common during and after breast and prostate cancer treatment. Here is how hormone treatments compare with the nonhormonal medicines, therapies and comfort steps that national guidelines list, and why the right choice depends on your cancer.
mammogram
Long-term Kisqali data, a new targeted drug, blood tests and AI are among the topics to watch at the 2026 San Antonio Breast Cancer Symposium.